GENE THERAPY GENESIS
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

GENE THERAPY GENESIS Trademark

Serial Number: 97697537

GENE THERAPY GENESIS is a trademark filed by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC on November 30, 2022. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC (19 trademarks)

411 SWEDELAND ROAD
KING OF PRUSSIA, PA 19406

Entity Type: 16

Trademark Details

Filing Date

November 30, 2022

Registration Date

Not Registered

Published for Opposition

December 12, 2023

Goods & Services

Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 9, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 9, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 6, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 12, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 22, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 8, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 6, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 6, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 18, 2023 GNRN
NON-FINAL ACTION E-MAILED
Sep 18, 2023 GNRT
NON-FINAL ACTION WRITTEN
Sep 18, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 22, 2022 NWOS
NEW APPLICATION ENTERED
Dec 3, 2022 NWAP